Sino Biopharmaceutical has entered into an exclusive promotion agreement with Beijing Puqi Pharmaceutical Technology for their innovative autoimmune drug, Pumeixiti Ni Gel. This collaboration grants Sino Biopharmaceutical exclusive rights to promote the gel across all dermatological indications in mainland China, Hong Kong, and Macau. The drug's new drug application for adult and adolescent atopic dermatitis has already been accepted by China's National Medical Products Administration. AI
RANK_REASON Partnership agreement for exclusive promotion of a drug with an accepted NDA. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →